Vaxiion Therapeutics

Vaxiion Therapeutics is a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies. Our lead product, VAX014, is a novel alternative to oncolytic viral therapy and is currently undergoing clinical trials for the local treatment of bladder cancer. Based on the observed clinical activity in bladder cancer patients and strong additional preclinical data, the company will soon initiate a clinical trial for local delivery of VAX014 to other solid tumor types.